Cost analysis of DNA-based testing in a large Canadian family with multiple endocrine neoplasia type 2

Clinical Genetics

Volumn 66, Issue 4, 2004, Pages 349-352

  Gilchrist, Dawna M ^a   Morrish, D W ^a   Bridge, P J ^b   Brown, J L ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

Author keywords

Cost analysis; Genetic testing; Multiple endocrine neoplasia

Indexed keywords

ARGININE; CYSTEINE; GUANINE; PROTEIN RET; TYROSINE;

ADOLESCENT; ADULT; ARTICLE; CANADA; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST CONTROL; DNA DETERMINATION; EXON; FAMILY SIZE; FAMILY STUDY; FEMALE; GENE MUTATION; GENETIC ANALYSIS; HEALTH CARE COST; HIRSCHSPRUNG DISEASE; HUMAN; HUMAN CELL; MALE; MISSENSE MUTATION; MORBIDITY; MORTALITY; NEUROFIBROMATOSIS; POINT MUTATION; PRIORITY JOURNAL; RELATIVE; RISK ASSESSMENT; SIBLING; SIPPLE SYNDROME; THYROID MEDULLARY CARCINOMA;

CANADA; CARCINOMA, MEDULLARY; COSTS AND COST ANALYSIS; DNA; DNA MUTATIONAL ANALYSIS; FAMILY; FEMALE; GENETIC SCREENING; GERM-LINE MUTATION; HIRSCHSPRUNG DISEASE; HUMANS; MALE; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2B; ONCOGENE PROTEINS; PEDIGREE; PROTO-ONCOGENE PROTEINS C-RET; RECEPTOR PROTEIN-TYROSINE KINASES; THYROID NEOPLASMS; THYROIDECTOMY;

EID: 4844223240     PISSN: 00099163     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-0004.2004.00312.x     Document Type: Article

References (13)

1. Morgan S. Predictive genetic tests and health system costs. CMAJ 2003: 168 (8): 989-991.
2. Ponder B. Costs, benefits and limitations of genetic testing for cancer risk. Cancer 1999: 80 (Suppl. 1): 46-50.
3. Eng C. The RET proto-oncogene in multiple endocrine neoplasia type 2 and Hirschsprung's disease. N Engl J Med 1996: 335 (13): 943-951.
4. Mulligan L, Kwok J, Healey C et al. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 1993: 363: 458-460.
5. Donis-Keller H, Dou S, Chi D. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet 2003: 2: 851-856.
6. Brandi M, Gagel R, Angeli A et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 2001: 86 (12): 5658-5671.
7. Machens A, Gimm O, Hinze R, Hoppner W, Boehn B, Dralle H. Genotype-phenotype correlations in hereditary medullary thyroid carcinoma: oncological features and biochemical properties. J Clin Endocrinol Metab 2001: 86 (3): 1104-1109.
8. Lips C, Landsvater R, Hoppener J et al. Clinical screening as compared with DNA analysis in families with multiple endocrine neoplasia type 2A. N Engl J Med 1994: 331 (13): 828-835
9. Machens A, Niccoli-Sire P, Hoegel J et al. Early malignant progression of hereditary medullary thyroid cancer. N Engl J Med 2003: 349 (16): 1517-1525.
10. Sanso G, Domene H, Pudaz MG et al. Very early detection of RET proto-oncogene mutation is crucial for preventive thyroidectomy in multiple endocrine neoplasia type 2 children. Cancer 2002: 94 (2): 323-330.
11. Pichert G, Bolliger B, Buser K, Pagani O. Evidence-based management options for women at increased breast/ovarian cancer risk. Ann Oncol 2003: 14: 9-19.
12. DeFrancisco J, Grady WM. Diagnosis and management of hereditary non-polyposis colon cancer. Gastrointest Endosc 2003: 58 (3): 390-408.
13. American Society of Clinical Oncology Policy Statement Update: genetic testing for cancer susceptibility. J Clin Onc 2003: 12 (15): 2397-2406.